DEERFIELD, Ill. / Jan 22, 2025 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2024 financial results on Thursday, February 13, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I2823858 to pre-register for the call and receive the call information.
This call is also being webcast and can be accessed through Baxter’s website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter’s permission.
About Baxter
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.
Last Trade: | US$30.05 |
Daily Change: | 0.24 0.81 |
Daily Volume: | 2,906,395 |
Market Cap: | US$15.420B |
July 07, 2025 May 01, 2025 March 04, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load